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Abstract

Objectives
To evaluate the relationship between erythrocyte parameters and the presence or absence of
arthritis in HFE C282Y homozygous haemochromatosis (HH) subjects compared to control
groups of non-HH subjects with arthritis.
Methods
Erythrocyte and arthritis parameters (mean cell volume, MCV and mean cell haemoglobin,
MCH) were obtained from consecutive HH subjects (n=119) who were referred for initial
evaluation and management. For comparison purposes, MCV and MCH values were
collected from randomly selected non-HH subjects with rheumatoid arthritis (n=100) and
osteoarthritis (n=100), consisting of equal numbers of men and women. Two other
comparison groups comprised of 16 men and women who were heterozygous for C282Y with
arthritis and 38 non-HH subjects with type 2 polyarticular osteoarthritis.
Results
MCV values were significantly higher in HH subjects with arthritis (95 ± 0.56 fL) than in HH
subjects without arthritis (92.75 ± 0.50 fL, p=0.037). HH subjects with or without arthritis
demonstrated a higher mean MCV compared to the control groups of non-HH osteoarthritis
(90.12 ± 0.46 fL, p <0.001) and non-HH rheumatoid arthritis (90.94 ± 0.57 fL, p<0.001). HH
subjects with arthritis also demonstrated a higher MCV when compared with heterozygous
C282Y subjects with arthritis (93.18 ± 1.55 fL, p=0.025) and non-HH subjects with a similar
pattern of arthritis, notably T2POA (91.13±0.50 fL, p<0.01). A MCV of 97.85 fL or greater
provided a likelihood ratio of 2.2 for the development of arthritis in HH subjects.

Conclusion
This study has demonstrated a relationship between elevated MCV and arthritis in incident
cases of HH.

1. Introduction
HFE haemochromatosis (HH) is an iron overload disorder affecting 1 in 200 individuals of
northern European descent (1), usually caused by a homozygous C282Y mutation in the HFE
gene (2,3). Up to 30% of individuals homozygous for C282Y may develop significant disease
from iron overload, including HH-related arthropathy (4). HH-arthropathy was first described
by Schumacher in 1964 and affects up to 81% of subjects (5). It is a significant cause of
morbidity, disability and reduced quality of life (6). Classically, arthropathy affects the
finger metacarpophalangeal (MCP) joints and other joints such as the hips, ankles, radiocarpal, elbow, shoulder and knee joints as well as the lumbar spine (7). It is unclear why
arthropathy affects only a subset of people with HH, or whether it can be predicted.
Previous studies have reported that subjects with HH exhibit significant differences in
peripheral blood erythrocyte parameters compared with controls (8,9). The mean cell volume
(MCV) was elevated compared with healthy controls or those without HH, but with a range
of joint diseases, predated the development of elevated body iron stores and persisted
following therapeutic phlebotomy (9). Similarly, the arthritis of HH can also predate the
development of iron overload and persist following phlebotomy therapy. Whether these HFErelated changes in erythrocyte parameters have predictive value in respect to arthritis in HH is
unknown.
2. Aim
The aim of this study was to evaluate the relationship between erythrocyte parameters and the
presence or absence of arthritis in HH subjects compared to randomly selected control groups
of non-HH subjects with osteoarthritis and rheumatoid arthritis.
3. Methods
3.1 Participants

Between 2005 and 2015 consecutive HH subjects aged between 22 and 70 years with C282Y
homozygosity who were referred for diagnosis, management and who underwent liver biopsy
were included (n=119). Laboratory investigations included haematology, serum iron
biochemistry, HH genotyping, liver biochemistry, chronic viral hepatitis serology, screens for
autoimmune liver disease, Wilson disease and alpha-1 antitrypsin genotype. Hepatic iron
concentration (HIC) was measured (10) and hepatic fibrosis graded (11). Exclusion criteria
were: pregnant or lactating women, venesection in the previous 12 months, malignancy and
acute inflammatory conditions. 66 of 119 HH subjects had arthritis (64 MCP 2,3 arthropathy,
20 both MCP and other joints). As characterization of arthropathy was not one of the routine
clinical study objectives in the HH cohort, plain X-rays were not systematically undertaken.
Phlebotomy treatment was performed weekly on all subjects until a serum ferritin level of
less than 100µg/L was achieved, and the iron removed calculated as previously described
(12). A second group of 16 men and women heterozygous for C282Y and in whom MCP 2,3
arthropathy with radiological features consistent with those observed in HH, but in whom
there was no iron overload were included for comparison purposes. To evaluate differences
with other chronic forms of arthritis, we randomly selected non-HH participants with
rheumatoid arthritis (n=100) and osteoarthritis (n=100), consisting of equal numbers of men
and women. Furthermore, a convenience sample of 38 participants who had clinically
apparent type 2 polyarticular osteoarthritis involving the MCP 2,3 joints (T2POA) with
radiological features consistent with those observed in HH, but in whom there was no iron
overload and no detectable HFE gene mutations was also included for comparison purposes.
The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was
approved by the QIMR Berghofer Medical Research Institute Human Research Ethics
Committee.
3.2 Statistical analysis

All data are presented as mean ± SEM. Analysis of variance was used to determine
significance of differences between groups using Brown-Forsyth and Welch’s tests.
Sensitivity and specificity analysis were performed using receiver operator characteristic
curve analysis. Multivariate logistic regression analysis, including variables that were
statistically significantly different in univariate analysis, was used to calculate the odds ratio
(OR) for predictors of arthritis in subjects with HH. (Prism 8, GraphPad Software, CA).
Statistical significance was assigned for p<0.05.
4. Results
Clinical characteristics of study subjects at initial diagnosis are shown in Table 1. MCV
values were significantly higher in HH subjects exhibiting arthritis (95.00 ± 0.56 fL) versus
HH subjects without arthritis (92.75 ± 0.50 fL, p=0.0375) (Figure 1), especially male HH
subjects (95.33 ± 0.71 fL with arthritis versus 92.47 ± 0.72 fL without, p< 0.01). MCV
values for the total combined group of all HH subjects with or without arthritis (93.87 ± 0.41
fL) and those with arthritis-only (95.00 ± 0.56 fL) were significantly higher when compared
to the control groups of non-HH osteoarthritis (MCV 90.12 ± 0.46 fL, p <0.001) and non-HH
rheumatoid arthritis (MCV 90.94 ± 0.57 fL, p<0.001) (Table 1). MCV values in the non-HH
rheumatoid arthritis and osteoarthritis groups were similar. Subjects heterozygous for the
C282Y mutation had significantly lower MCV values than HH subjects with arthritis (93.18
± 1.55 vs 95 ± 0.56 fL, respectively, p=0.025), however there was no significant difference
when compared with HH subjects without arthritis or non-HH subjects with osteoarthritis or
rheumatoid arthritis. Sensitivity and specificity analyses demonstrated that a MCV of 97.85
fL or greater provided a likelihood ratio of 2.2 for the development of arthritis in HH
subjects. No significant differences were observed for MCH in any of the cohorts.

Transferrin saturation was similar in HH subjects with or without arthritis (Table 1).
Serum ferritin levels, HIC and iron removed were significantly higher in HH subjects with
arthritis compared to those without (Table 1). Hepatic fibrosis was significantly greater in HH
subjects with arthritis compared to those without (median Scheuer score 1 in those with
arthritis versus 0 in those without fibrosis, p<0.0001, Mann Whitney test). Using linear
regression analysis, no relationships were observed between MCV and either serum ferritin,
HIC or iron removed. Multivariable logistic regression analysis confirmed fibrosis severity
(OR 2.2, CI 1.1-4.7) and iron removal (OR 1.5, CI 1.3-2.3) exhibited ongoing association
with arthritis.
5. Discussion
HH arthropathy is an aetiologic enigma and therapeutic challenge. Lack of insight into the
mechanism responsible for joint disease in HH hinders the development of possible therapy
and an inability to predict onset precludes the early implementation of possible corrective
measures.
Our observation that HH arthropathy segregates with an elevated MCV needs to be verified
in independent studies, but if confirmed, may permit earlier prediction of impending
arthropathy and create opportunities for preventive and treatment strategies. Previous work
shows that elevation of MCV precedes the elevation of serum ferritin levels in HH (9). Here
we extend this observation by showing that MCV, iron burden, and liver fibrosis all associate
HH-arthritis. Interestingly, the lack of a relationship between MCV and either HIC or iron
removed suggests that the elevated MCV of HH is independent of increased iron burden per
se. The MCV changes may be due to the direct effects of C282Y mutations in HFE per se. It
is known that the HFE protein is not expressed in erythrocytes (13), with the elevated MCV
in subjects with HH possibly being due to increased iron supply to erythroblasts (8). A

similar phenomenon could be occurring in cells that contribute to the genesis of arthritis.
Thus, MCV may allow prediction of arthropathy propensity and allow scrutiny of those
considered to be at greater risk. Indeed, our retrospective analysis demonstrated that a MCV
of 97.85 fL or greater provided a 2.2-fold increased likelihood of development of arthritis in
HH subjects.
Most information regarding disease pathogenesis in HH joints has been derived from surgical
specimens obtained at joint replacement surgery, demonstrating iron deposition in joint
synovium and cartilage (haemosiderin) (14, 15). Higher ferritin concentrations in synovial
fluid, particularly prior to HH diagnosis and phlebotomy, may lead to greater uptake by
synovial cells (fibroblasts and macrophages) and a substantial tissue deposition of iron, like
the way urate accumulates until urate lowering therapy is used to treat gout. Likewise,
chondrocytes may accumulate diffusible ferritin. Collectively these events, may lead to iron
trapping and irreversible cellular iron accumulation. Over time, irreversible joint damage and
painful arthropathy may ensue.
Strengths of this study include substantial numbers of participants, adequate numbers of
controls including HFE heterozygous participants with similar arthropathy in whom both
genders are well represented and the inclusion of both RA and OA control groups without
HH. Weaknesses include the lack of radiographic evidence validating the arthropathies (all
were physician diagnosed and supported by relevant laboratory data). No joint tissues were
available to correlate findings.
Conclusion
In HH, elevated MCV segregates with arthropathy, unlike in osteoarthritis and rheumatoid
arthritis. The mechanism underlying the erythrocyte manifestations is unclear. One possibility
is that the increased erythrocyte MCV may be a function of dysregulated iron metabolism in

erythroblasts or abnormal intracellular iron processing in this cell lineage. A similar
phenomenon may occur in joint tissues, which may in turn lead to iron-trapping and
subsequent tissue damage. Whether perturbations of erythrocyte size may reflect iron
deposition in joint tissues, including synovium, or iron retention in such tissues and so
predispose to arthropathy, warrants further investigation.
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Figure legend
Figure 1. MCV in HH subjects with or without arthritis and control arthritis groups including
osteoarthritis, rheumatoid arthritis, C282Y heterozygotes with MCP 2,3 arthritis and nonHFE gene mutation subjects with type 2 polyarticular osteoarthritis (T2POA) involving the
MCP 2,3 joints (T2POA). Values are shown as the mean  SEM. *p<0.05; **p<0.01;
***p<0.001 compared with the HH subjects with arthritis.

Table 1. Characteristics of HH subjects, with or without arthritis, osteoarthritis, rheumatoid arthritis, C282Y heterozygotes with arthritis and
subjects with osteoarthritis resembling HH but without HFE mutations or iron overload.
HH Subjects

Non-HH subjects
OA resembling HH

Arthritis

No arthritis

Osteoarthritis

Rheumatoid arthritis

Heterozygotes
arthropathy (T2POA)

n (M/F)

66 (38/28)

53 (37/16)

100 (50/50)

100 (50/50)

16 (7/9)

38 (24/14)

49 ± 2

40 ± 2

56 ± 2

62 ± 2

70 ± 2

74 ± 1.3

95.00 ± 0.56

92.75 ± 0.50*

90.12 ± 0.46***

90.94 ± 0.57***

93.18 ± 1.55*

91.13 ± 0.45**

32.38 ± 0.23

31.86 ± 0.20

30.12 ± 0.20

30.14 ± 0.23

31.30 ± 0.30

30.04 ± 0.30

Age ± SEM
(yrs)

MCV ±
SEM (fL)

MCH ±
SEM (pg)

TSat ±
85 ± 2

80 ± 2

1966±151

807±70 g/L***

237 ± 15

151 ± 10***

11.6 ± 0.9

5.0 ± 0.4***

SEM (%)
Ferritin ±
SEM (g/L)
HIC ± SEM
(mol/g)
Iron ± SEM
removed (g)
HIC – hepatic iron concentration; MCH – mean cell haemoglobin; MCV – mean cell volume; OA – osteoarthritis; T2POA – type 2 polyarticular arthritis
involving the MCP 2,3 joints; TSat – transferrin saturation. Iron parameters are only presented for the HH subjects. All statistical comparisons are with the HH
arthritis group. *p<0.05; **p<0.01; ***p<0.001.

